908 Devices (MASS)
(Delayed Data from NSDQ)
$3.53 USD
+0.09 (2.62%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.47 -0.06 (-1.70%) 6:26 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.53 USD
+0.09 (2.62%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.47 -0.06 (-1.70%) 6:26 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Zacks News
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices (MASS) delivered earnings and revenue surprises of 5.88% and 2.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
ClearPoint Neuro (CLPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: 908 Devices Inc. (MASS) Q2 Earnings Expected to Decline
by Zacks Equity Research
908 Devices (MASS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Predict a 133.69% Upside in 908 Devices (MASS): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 133.7% in 908 Devices (MASS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
908 Devices (MASS) Loses -9.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
908 Devices (MASS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices (MASS) delivered earnings and revenue surprises of 10.81% and 6.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intuitive Surgical, Inc. (ISRG) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of 7.14% and 1.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nevro (NVRO) delivered earnings and revenue surprises of 70% and 0.22%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
908 Devices Inc. (MASS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
How Much Upside is Left in 908 Devices Inc. (MASS)? Wall Street Analysts Think 100.39%
by Zacks Equity Research
The consensus price target hints at a 100.4% upside potential for 908 Devices Inc. (MASS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices Inc. (MASS) delivered earnings and revenue surprises of 12.12% and 16.74%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Shockwave Medical (SWAV) Misses Q2 Earnings Estimates
by Zacks Equity Research
Shockwave Medical (SWAV) delivered earnings and revenue surprises of -12.64% and 3.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 5.99% and 2.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Avinger (AVGR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Avinger (AVGR) delivered earnings and revenue surprises of -20.41% and 11.26%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Soars 8.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
908 Devices Inc. (MASS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices Inc. (MASS) delivered earnings and revenue surprises of -11.43% and 9.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Veracyte (VCYT) delivered earnings and revenue surprises of 21.43% and 6.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices Inc. (MASS) delivered earnings and revenue surprises of -40.91% and 1.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 12.82% and 2.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ViewRay (VRAY) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ViewRay (VRAY) delivered earnings and revenue surprises of 6.25% and 0.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical (GMED) Tops Q4 Earnings Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 7.27% and 0.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices Inc. (MASS) delivered earnings and revenue surprises of 9.09% and 0.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Dynatronics Corporation (DYNT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of 33.33% and 2.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of -10% and 4.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?